Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. (not Altimmune, Inc.) on July 30, 2009, reporting events occurring on July 24, 2009. The filing details a private placement transaction involving the issuance of senior convertible notes and common stock purchase warrants to existing and new investors.
Key Financial Metrics and Transaction Details
- Gross Cash Proceeds: Approximately $10.5 million from new investors, including $8.5 million from unaffiliated investors.
- Debt Restructuring: Approximately $8.8 million in outstanding principal and accrued interest from 2007 "Old Notes" was canceled and exchanged for new Notes and Warrants.
- New Debt Instrument: 2-year, 10% unsecured senior convertible notes with a maturity date of July 28, 2011.
- Conversion Terms: Notes are convertible into up to 7.6 million shares of common stock at a price of $2.541667 per share.
- Warrant Terms: Warrants issued to purchase up to 2.6 million shares at $2.50 per share, exercisable for five years beginning six months post-closing.
- Liquidity Impact: The transaction provided immediate cash inflow and reduced existing debt obligations.
Material Changes and Governance
The transaction resulted in significant changes to the company's capital structure and governance:
- Board Composition: Investors gained the right to elect two directors to the Board of Directors, who may serve on the Nominating and Compensation Committees.
- Debt Covenants: The company is restricted from incurring senior indebtedness exceeding $10 million without investor approval. Investors also hold a right of first refusal on senior indebtedness.
- Registration Rights: A Registration Rights Agreement requires the company to file a registration statement within 30 days of closing and use best efforts to make it effective within 90 days (or 120 days if reviewed by the SEC).
Risks, Contingencies, and Unusual Items
The filing outlines specific events of default that could trigger immediate repayment of the Notes:
- Bankruptcy: The Notes become immediately due and payable in the event of bankruptcy.
- Legal Judgments: A final judgment for the payment of money greater than $5 million triggers immediate repayment.
- Governance Failure: Failure to include at least two directors selected by noteholders on the Board while at least 30% of the aggregate principal amount of the Notes is outstanding triggers immediate repayment.
The filing text does not provide specific revenue, profit, or operating margin data for the period.
Investor Verification Checklist
- Verify the effective date of the registration statement for the shares issuable upon conversion and warrant exercise.
- Confirm the appointment of the two investor-elected directors to the Board of Directors.
- Monitor the company's compliance with the $10 million senior indebtedness cap.
- Assess the dilution impact of the potential issuance of 7.6 million convertible shares and 2.6 million warrant shares.
- Review the company's cash burn rate to ensure sufficient liquidity to service the 10% interest on the new Notes until maturity in 2011.